Crispr Therapeutics AG (NASDAQ:CRSP) – Analysts at Piper Jaffray Companies increased their Q1 2020 earnings estimates for shares of Crispr Therapeutics in a research note issued to investors on Tuesday, November 26th. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the company will post earnings of ($1.20) per share for the quarter, up from their prior estimate of ($1.29). Piper Jaffray Companies currently has a “Buy” rating and a $104.00 price target on the stock. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million.
Other analysts have also issued research reports about the company. Chardan Capital reiterated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a report on Monday, November 18th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Oppenheimer raised their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Finally, Canaccord Genuity raised their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company. Crispr Therapeutics presently has an average rating of “Buy” and an average price target of $69.54.
CRSP opened at $71.65 on Thursday. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The firm has a market capitalization of $3.80 billion, a PE ratio of -20.83 and a beta of 3.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The business’s 50-day simple moving average is $49.98 and its 200 day simple moving average is $46.23.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Nikko Asset Management Americas Inc. grew its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares during the last quarter. ARK Investment Management LLC grew its position in Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after buying an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares during the last quarter. Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new position in Crispr Therapeutics in the 3rd quarter valued at $21,167,000. Institutional investors and hedge funds own 49.81% of the company’s stock.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Gap Down Stocks
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.